Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.

@article{Nadali1998SerumLO,
  title={Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.},
  author={Gianpaolo Nadali and Luisa Tavecchia and Elisabetta Maria Zanolin and Valeria Bonfante and Simonetta Viviani and Emilio Camerini and Pellegrino Musto and Nicola di Renzo and Marco Carotenuto and Marco Chilosi and Mauro Krampera and Giovanni Pizzolo},
  journal={Blood},
  year={1998},
  volume={91 8},
  pages={3011-6}
}
Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin's disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration at diagnosis in relation to the other recognized prognostic parameters in 303 patients with HD observed in three different institutions between 1984 and 1996. sCD30 levels were correlated with stage, presence of B symptoms, and tumor burden. High sCD30 levels entailed a higher risk of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

A numerical index to predict tumor control in advanced Hodgkin’s disease

  • D Hasenclever, V Diehl
  • Blood 88:673a,
  • 1996

Similar Papers

Loading similar papers…